Vivek M Shastri,
Postdoctoral Associate
Department:
Pharmacotherapy & Translational Research
Business Phone:
(352) 273-6236
Business Email:
vivekshastri@ufl.edu
Publications
2024
Genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML: a report from the Children’s Oncology Group.
Clinical cancer research : an official journal of the American Association for Cancer Research.
[DOI] 10.1158/1078-0432.CCR-23-2073.
[PMID] 38197878.
2022
A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
Leukemia.
36(8):2022-2031
[DOI] 10.1038/s41375-022-01622-0.
[PMID] 35688939.
2021
A novel cell-cycle-regulated interaction of the Bloom syndrome helicase BLM with Mcm6 controls replication-linked processes.
Nucleic acids research.
49(15):8699-8713
[DOI] 10.1093/nar/gkab663.
[PMID] 34370039.
2021
Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.
Future oncology (London, England).
17(3):263-277
[DOI] 10.2217/fon-2020-0746.
[PMID] 33356566.
2016
Cellular defects caused by hypomorphic variants of the Bloom syndrome helicase gene BLM.
Molecular genetics & genomic medicine.
4(1):106-19
[DOI] 10.1002/mgg3.188.
[PMID] 26788541.
Contact Details
Phones:
- Business:
- (352) 273-6236
Emails:
- Business:
- vivekshastri@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100486
GAINESVILLE FL 32610